TipRanks
Advertisement
Advertisement

CTSO Stock Latest News

CytoSorbents initiated with a Speculative Buy at WBB Securities
The FlyCytoSorbents initiated with a Speculative Buy at WBB Securities
37m ago
CTSO
CytoSorbents Regains Nasdaq Compliance, Pursues Growth Initiatives
PremiumCompany Announcements
CytoSorbents Regains Nasdaq Compliance, Pursues Growth Initiatives
28d ago
8K
CTSO
CytoSorbents Announces One-for-Twenty Reverse Stock Split
PremiumCompany Announcements
CytoSorbents Announces One-for-Twenty Reverse Stock Split
1M ago
8K
CTSO
Upcoming Stock Splits This Week (September 7 to September 11) – Stay Invested
PremiumMarket News
Upcoming Stock Splits This Week (September 7 to September 11) – Stay Invested
1M ago
ALP
IGR
CytoSorbents trading halted, news pending
PremiumThe Fly
CytoSorbents trading halted, news pending
2M ago
CTSO
CytoSorbents announces 1-for-20 reverse stock split
PremiumThe FlyCytoSorbents announces 1-for-20 reverse stock split
2M ago
CTSO
CytoSorbents announces real-world data using CytoSorb
Premium
The Fly
CytoSorbents announces real-world data using CytoSorb
2M ago
CTSO
Cytosorbents Earnings Call Balances Progress and Risk
Premium
Company Announcements
Cytosorbents Earnings Call Balances Progress and Risk
2M ago
CTSO
CytoSorbents Shareholders Approve Governance Measures and Reverse Split
PremiumCompany Announcements
CytoSorbents Shareholders Approve Governance Measures and Reverse Split
2M ago
8K
CTSO
Cytosorbents Advances Toward Operating Cash Flow Breakeven
PremiumCompany Announcements
Cytosorbents Advances Toward Operating Cash Flow Breakeven
2M ago
8K
CTSO
CytoSorbents: Neutral Rating Reiterated as Operational Progress Offsets Market and Regulatory Risks; $0.75 Price Target Maintained
PremiumRatings
CytoSorbents: Neutral Rating Reiterated as Operational Progress Offsets Market and Regulatory Risks; $0.75 Price Target Maintained
3M ago
CTSO
Is CTSO a Buy, Before Earnings?
PremiumPre-Earnings
Is CTSO a Buy, Before Earnings?
3M ago
CTSO
Cytosorbents Faces Nasdaq Compliance and Delisting Risk
PremiumCompany AnnouncementsCytosorbents Faces Nasdaq Compliance and Delisting Risk
4M ago
8K
CTSO
CytoSorbents Advances FDA Pathway for DrugSorb Programs
Premium
Company Announcements
CytoSorbents Advances FDA Pathway for DrugSorb Programs
4M ago
8K
CTSO
Cytosorbents Earnings Call Balances Progress and Pressure
Premium
Company Announcements
Cytosorbents Earnings Call Balances Progress and Pressure
5M ago
CTSO
Cytosorbents Earnings Call Balances Progress And Pressure
PremiumCompany Announcements
Cytosorbents Earnings Call Balances Progress And Pressure
5M ago
CTSO
CytoSorbents reports Q1 adjusted EPS (5c) vs. (6c) last year
PremiumThe Fly
CytoSorbents reports Q1 adjusted EPS (5c) vs. (6c) last year
5M ago
CTSO
CTSO Earnings this Week: How Will it Perform?
PremiumPre-Earnings
CTSO Earnings this Week: How Will it Perform?
6M ago
CTSO
CytoSorbents Receives Nasdaq Extension to Regain Compliance
PremiumCompany Announcements
CytoSorbents Receives Nasdaq Extension to Regain Compliance
7M ago
8K
CTSO
Cytosorbents’ Earnings Call Balances Progress and Risk
PremiumCompany AnnouncementsCytosorbents’ Earnings Call Balances Progress and Risk
7M ago
CTSO
CytoSorbents: Neutral Stance as U.S. DrugSorb-ATR Opportunity Offsets Near-Term Execution and Regulatory Risks
Premium
Ratings
CytoSorbents: Neutral Stance as U.S. DrugSorb-ATR Opportunity Offsets Near-Term Execution and Regulatory Risks
7M ago
CTSO
CytoSorbents Narrows Losses Amid Strategic Shift and Growth
Premium
Company Announcements
CytoSorbents Narrows Losses Amid Strategic Shift and Growth
7M ago
8K
CTSO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >